Eledon Pharmaceuticals (ELDN) Long-Term Deferred Tax (2013 - 2016)

Eledon Pharmaceuticals' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $65.6 million for Q4 2016.

• Quarterly Long-Term Deferred Tax rose 28.64% year-over-year to $65.6 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $65.6 million (up 28.64% YoY) and the FY2016 annual result came in at $65.6 million, up 28.64% from the prior year.
• Long-Term Deferred Tax was $65.6 million for Q4 2016 at Eledon Pharmaceuticals, up from $51.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $65.6 million in Q4 2016 and bottomed at $24.4 million in Q4 2013.
• A 4-year average of $43.6 million and a median of $42.2 million in 2014 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2015 — Long-Term Deferred Tax surged 53.37% — and 2016, when it gained 28.64%.
• Eledon Pharmaceuticals' Long-Term Deferred Tax stood at $24.4 million in 2013, then soared by 36.35% to $33.3 million in 2014, then jumped by 53.37% to $51.0 million in 2015, then advanced by 28.64% to $65.6 million in 2016.
• Business Quant data shows ELDN's Long-Term Deferred Tax at $65.6 million in Q4 2016, $51.0 million in Q4 2015, and $33.3 million in Q4 2014.